Storia in 6 fonti

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

Raccontata da

Confronto fonti

6 prospettive sulla stessa storia

AI · summaries

biopharmadive.comStai leggendo3 g fa

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.

originale

Timeline cronologica

lunedì 10 agosto 2026·biopharmadive.com
Sionna cystic fibrosis drug fails key trial, removing threat to Vertex
Sionna’s medicine didn’t have a meaningful additive impact when combined with Vertex’s top-selling Trikafta, surprising analysts and collapsing company shares.
lunedì 10 agosto 2026·statnews.com
Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial
A pill from Sionna Therapeutics provided no added benefit when combined with Vertex's cystic fibrosis blockbuster Trikafta, a blow to the biotech.

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Confronto fonti

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Timeline cronologica

Sionna cystic fibrosis drug fails key trial, removing threat to Vertex

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Sionna’s experimental cystic fibrosis pill falls flat in mid-stage trial

Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks - Sion

Sionna Therapeutics stock falls 92% after SION-719 trial failure

Vertex Pops As A Key Rival Plummets 90%

Vertex Pops As A Key Rival Plummets 90%

Sionna's surprise cystic fibrosis trial failure sinks hopes of challenging Vertex

Sionna Therapeutics Discontinues Cystic Fibrosis Drug Following Unfavorable Data Data, Stock Tanks - Sion

Sionna Therapeutics stock falls 92% after SION-719 trial failure